InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Argenica Therapeutics Limited (ASX: AGN) - Announcements

- Current share price for AGN : $0.140

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Half Yearly Report and Accounts 11 Feb 2025 6:17PM $0.760 $0.140 fallen by 81.58%
$18 Updated - Main TBI Injury Study Annoucement 4 Feb 2025 10:08AM $0.765 $0.140 fallen by 81.70%
$18 ARG-007 Shows Significant Neuroprotection in Main TBI Study 4 Feb 2025 9:23AM $0.700 $0.140 fallen by 80%
$18 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2025 9:23AM $0.655 $0.140 fallen by 78.63%
$18 Positive DSMB Safety Outcome & Phase 2 Trial Progress Update 30 Jan 2025 9:17AM $0.655 $0.140 fallen by 78.63%
$18 Phase 2 Stroke Clinical Trial Update 10 Dec 2024 9:58AM $0.655 $0.140 fallen by 78.63%
$18 Initial Director's Interest Notice 2 Dec 2024 8:20AM $0.695 $0.140 fallen by 79.86%
$18 Non-Executive Director Appointment 2 Dec 2024 8:20AM $0.695 $0.140 fallen by 79.86%
$18 $2.76m R&D Tax Incentive Cash Rebate Received for FY24 21 Nov 2024 8:17AM $0.700 $0.140 fallen by 80%
$18 Final Director's Interest Notice 13 Nov 2024 8:52AM $0.770 $0.140 fallen by 81.82%
$18 AGM Chair's Address & MD Presentation 13 Nov 2024 8:26AM $0.770 $0.140 fallen by 81.82%
$18 Results of Annual General Meeting 13 Nov 2024 8:26AM $0.770 $0.140 fallen by 81.82%
$18 Positive DSMB Safety Outcome & Phase 2 Trial Progress Update 1 Nov 2024 9:07AM $0.785 $0.140 fallen by 82.17%
$18 Quarterly Activities/Appendix 4C Cash Flow Report - updated 31 Oct 2024 5:33PM $0.785 $0.140 fallen by 82.17%
$18 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2024 4:30PM $0.785 $0.140 fallen by 82.17%
$18 FDA Grants ODD & RPDD for Second Drug in Treatment of HIE 30 Oct 2024 12:25PM $0.730 $0.140 fallen by 80.82%
$18 Investor Presentation 29 Oct 2024 9:19AM $0.710 $0.140 fallen by 80.28%
$18 Non-Executive Director Retirement 24 Oct 2024 8:20AM $0.720 $0.140 fallen by 80.56%
$18 Notice of Annual General Meeting/Proxy Form 11 Oct 2024 11:58AM $0.760 $0.140 fallen by 81.58%
$18 Argenica Appoints VP of Product Development 7 Oct 2024 8:26AM $0.720 $0.140 fallen by 80.56%
$18 Positive Results in Key IND Enabling Studies 25 Sep 2024 9:40AM $0.665 $0.140 fallen by 78.95%
$18 Application for quotation of securities - AGN 24 Sep 2024 9:00AM $0.700 $0.140 fallen by 80%
$18 Initial Director's Interest Notice x2 17 Sep 2024 8:20AM $0.810 $0.140 fallen by 82.72%
$18 New Appointments to the Board of Directors 17 Sep 2024 8:20AM $0.810 $0.140 fallen by 82.72%
$18 Date of AGM & Closing Date For Director Nominations 17 Sep 2024 8:19AM $0.810 $0.140 fallen by 82.72%

76 - 100 of 297 results

Page 4 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.